|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01/09/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 01/01/2023 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 04/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 26/08/2016 |
Günter von Au
CHM | Chairman | 75 | 27/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| -0.97% | -3.00% | +14.44% | +62.03% | 47.02B | ||
| -1.83% | -6.44% | +33.94% | +110.41% | 39.94B | ||
| -1.05% | -1.08% | +6.16% | +76.26% | 11.82B | ||
| -1.70% | -2.56% | -13.53% | +8.20% | 11.57B | ||
| 0.00% | +0.38% | +20.28% | +137.27% | 9.18B | ||
| -0.72% | -2.50% | +24.28% | +32.94% | 7.32B | ||
| -1.26% | -1.85% | +12.43% | +194.98% | 7.22B | ||
| -1.09% | -5.25% | +33.87% | -18.63% | 7.2B | ||
| -1.43% | -1.37% | -43.32% | +21.01% | 5.2B | ||
| Average | -0.96% | -2.60% | +9.84% | +69.39% | 15.22B | |
| Weighted average by Cap. | -1.17% | -3.21% | +16.54% | +76.51% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















